Clinical Trial Detail

NCT ID NCT02279862
Title Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive
Recruitment Completed
Gender male
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

prostate cancer

Therapies

Ipilimumab

Age Groups: adult

No variant requirements are available.